S. M. Luger

1.2k total citations · 1 hit paper
14 papers, 949 citations indexed

About

S. M. Luger is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, S. M. Luger has authored 14 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 4 papers in Public Health, Environmental and Occupational Health and 4 papers in Immunology. Recurrent topics in S. M. Luger's work include Acute Myeloid Leukemia Research (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). S. M. Luger is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). S. M. Luger collaborates with scholars based in United States and Israel. S. M. Luger's co-authors include Barry Grimes, R. Rossi, Craig T. Jordan, SJ Szilvassy, GL Phillips, Todd E. Meyerrose, Mariusz Z. Ratajczak, AM Gewirtz, Lucia Catani and Nobuko Hijiya and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

S. M. Luger

14 papers receiving 926 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

2000 623 citations Craig T. Jordan, SJ Szilvassy et al. Leukemia profile →

Peers

S. M. Luger

HEMAT

MB

ONCOL

IMMUN

GENET

Xingwei Sui Japan

SJ Szilvassy Australia

Elisabeth Krömer Austria

Andrew Fong Canada

Robert C. Quackenbush United States

Nari Harakawa Japan

Ingbritt Åstrand‐Grundström Sweden

Olli Dufva Finland

Fei Fei United States

R. Rossi United States

Xingwei Sui Japan

S. M. Luger

331 ×0.7

HEMAT

329 ×0.8

MB

428 ×1.2

ONCOL

336 ×1.2

IMMUN

200 ×1.4

GENET

Citations per year, relative to S. M. Luger S. M. Luger (= 1×) peers Xingwei Sui

Countries citing papers authored by S. M. Luger

Since Specialization

Citations

This map shows the geographic impact of S. M. Luger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. M. Luger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. M. Luger more than expected).

Fields of papers citing papers by S. M. Luger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. M. Luger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. M. Luger. The network helps show where S. M. Luger may publish in the future.

Co-authorship network of co-authors of S. M. Luger

This figure shows the co-authorship network connecting the top 25 collaborators of S. M. Luger. A scholar is included among the top collaborators of S. M. Luger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. M. Luger. S. M. Luger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Ganzel, Chezi, Yihua Wang, Zijie Sun, et al.. (2024). Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials. Bone Marrow Transplantation. 59(9). 1215–1223. 1 indexed citations

2.

Fernández, Hugo F., Zhe Sun, Mark R. Litzow, et al.. (2009). A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. Journal of Clinical Oncology. 27(15_suppl). 7003–7003. 3 indexed citations

3.

García-Manero, G., S. M. Luger, Parameswaran Venugopal, et al.. (2009). A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. Journal of Clinical Oncology. 27(15_suppl). 7021–7021. 3 indexed citations

4.

Cook, Richard J., Patricia Mangan, S. M. Luger, et al.. (2008). Lenalidomide and stem cell collection in patients with multiple myeloma. Journal of Clinical Oncology. 26(15_suppl). 8547–8547. 2 indexed citations

5.

Yang, A S, Virginia M. Klimek, S. M. Luger, et al.. (2007). Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Journal of Clinical Oncology. 25(18_suppl). 7062–7062. 12 indexed citations

6.

Schuster, S. J., Elise A. Chong, Sunita D. Nasta, et al.. (2007). Effect of rituximab (R) on clinical outcomes after autologous stem cell transplantation (ASCT) in pts with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology. 25(18_suppl). 8122–8122. 1 indexed citations

7.

Stadtmauer, Edward A., Bruce L. Levine, David Porter, et al.. (2005). Co-stimulated autologous T-cell infusion after autologous stem cell transplantation (SCT) for myeloma accelerates lymphocyte recovery and augments response to pneumoccal vaccine: Results of a randomized trial. Journal of Clinical Oncology. 23(16_suppl). 6534–6534. 1 indexed citations

8.

Jordan, Craig T., SJ Szilvassy, Todd E. Meyerrose, et al.. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 14(10). 1777–1784. 623 indexed citations breakdown →

9.

Gewirtz, AM, S. M. Luger, & E. Stadtmauer. (1996). Bone marrow purging with oligodeoxynucleotides [letter; comment]. Blood. 88(4). 1517–1517. 12 indexed citations

10.

Luger, S. M., et al.. (1996). A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Blood. 87(4). 1326–1334. 19 indexed citations

11.

Ratajczak, Mariusz Z., Nobuko Hijiya, Lucia Catani, et al.. (1992). Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood. 79(8). 1956–1961. 64 indexed citations

12.

Ratajczak, Mariusz Z., Nobuko Hijiya, Lucia Catani, et al.. (1992). Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood. 79(8). 1956–1961. 78 indexed citations

13.

Ratajczak, Mariusz Z., et al.. (1992). Role of the KIT protooncogene in normal and malignant human hematopoiesis.. Proceedings of the National Academy of Sciences. 89(5). 1710–1714. 115 indexed citations

14.

Luger, S. M., John M. Kirkwood, Marc S. Ernstoff, & Daniel R. Vlock. (1990). High-Dose Cisplatin and Dacarbazine in the treatment of Metastatic Melanoma. JNCI Journal of the National Cancer Institute. 82(24). 1934–1937. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact